Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
30 mars 2022 08h00 HE
|
Prometheus Biosciences
- First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory pathways - - ATHENA-SSc-ILD Phase 2 topline results expected first-half 2024 - - FDA has...
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Progress
09 mars 2022 16h01 HE
|
Prometheus Biosciences
- Topline results for ongoing Phase 2 clinical trial in ulcerative colitis and Phase 2a trial in Crohn’s disease expected in fourth quarter 2022 - - Phase 2 trial in Systemic Sclerosis-Associated...
Prometheus Biosciences to Participate at the Cowen 42nd Annual Healthcare Conference
01 mars 2022 08h30 HE
|
Prometheus Biosciences
SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
07 févr. 2022 08h00 HE
|
Prometheus Biosciences
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference
12 janv. 2022 08h30 HE
|
Prometheus Biosciences
- Fast Track Designation granted from U.S. Food and Drug Administration for PRA023 for the treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) - - New patent granted for...
Prometheus Biosciences to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
05 janv. 2022 08h30 HE
|
Prometheus Biosciences
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone Payment
03 janv. 2022 08h00 HE
|
Prometheus Biosciences
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
07 déc. 2021 07h00 HE
|
Prometheus Biosciences
Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity Discussion of Phase 1...
Prometheus Biosciences Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Progress
12 nov. 2021 08h00 HE
|
Prometheus Biosciences
- Full clinical trial results from Phase 1a trial of PRA023 and announcement of a third Phase 2 indication for PRA023 expected in fourth quarter 2021 - - Enrollment on track for Phase 2 in...
Prometheus Biosciences to Present at Upcoming Investor Conferences
02 nov. 2021 08h00 HE
|
Prometheus Biosciences
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...